Harvard Bioscience, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Harvard Bioscience, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, equals 94% of its market value (net debt). Lower than 94% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
3.0×Over the last 3 years its own operating cash covered its investment spending (capex) 3.0 times.
Higher than 79% of Healthcare companies in United States.
Cash Locked Ratio
$38For every $100 of sales, $38 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $32 tied up three years earlier.
More money tied up than 79% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 24%
Sales fell 24% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-24% / -45%In 3 years sales changed by -24% while total assets changed by -45%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
4.4×Debt due within a year is covered 4.4 times by its yearly operating cash.
Higher than 79% of Healthcare companies in United States.
Cash Cushion Ratio
−94%Debt, after subtracting cash, equals 94% of its market value (net debt).
Lower than 94% of Healthcare companies in United States.
Tangible Assets Ratio
79%Of every $100 the company owns, $79 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 53% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 81% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Harvard Bioscience, Inc. made a loss over the last year. Harvard Bioscience, Inc. owes $0.90 for every $1 it owns. Harvard Bioscience, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossHarvard Bioscience, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.12The share price is 5.12 times Harvard Bioscience, Inc.'s book value per share, higher than 73% of Healthcare companies in United States.
Market cap
$38 MThe total market value of all of Harvard Bioscience, Inc.'s shares at today's price (share price × number of shares), smaller than 77% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$7 MWhat Harvard Bioscience, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.63Net worth divided by the number of shares. The share price of $8.34 is 5.1 times this, which is the P/B above.
Return on equity (ROE)
-90.0%Harvard Bioscience, Inc. lost 90.0% of its shareholders' money over the last year, lower than 68% of Healthcare companies in United States.
Owes vs Owns
0.90×Harvard Bioscience, Inc. owes $0.90 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Dividend yield
NoneHarvard Bioscience, Inc. does not currently pay a dividend.
Revenue growth
-8%Revenue fell 8% in the year to Dec 2025, and shrank 9% a year on average over 3 years.
Profit growth
LossHarvard Bioscience, Inc. made a loss in each of the last two years.
Profit margin
-65.5%Harvard Bioscience, Inc. lost $66 for every $100 of revenue.
Interest cover
0.0×Harvard Bioscience, Inc.'s operating profit covered its interest costs 0.0 times in the year to Dec 2025.
Cash vs debt
Net debtHarvard Bioscience, Inc. had $36 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Harvard Bioscience, Inc.: $38 M ÷ $7 M (30 Jun 2026) = 5.1.
What is Harvard Bioscience, Inc.'s return on equity?
Harvard Bioscience, Inc. lost 90.0% of its shareholders' money over the last year, lower than 68% of Healthcare companies in United States.
How much does Harvard Bioscience, Inc. owe compared with what it owns?
Harvard Bioscience, Inc. owes $0.90 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Does Harvard Bioscience, Inc. pay a dividend?
No. Harvard Bioscience, Inc. does not currently pay a dividend.
Is Harvard Bioscience, Inc.'s revenue growing?
Revenue fell 8% in the year to Dec 2025, and shrank 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.